Acute Coronary Syndrome

Overview

Definition and Pathophysiology

Clinical Presentation

Differential Diagnosis

Diagnostic Tests

Management

Medications

Complications

Patient Education

References and Guidelines

Notes for HCPs

Clinical Highlights

Recommended reads

Field	Triage	Clinical Setting	Condition Type
Cardiology	Emergency	ICU	Acute

Overview

Condition

Name: Acute Coronary Syndrome (ACS).

ICD-10 Codes:

• I20 = Angina pectoris:
  - I20.0 = Unstable angina.
  - I20.1 = Angina pectoris with documented spasm.
  - I20.8 = Other forms of angina pectoris.
  - I20.9 = Angina pectoris, unspecified.
• I21 = Acute myocardial infarction (AMI):
  - I21.0 = Acute transmural myocardial infarction of anterior wall (STEMI involving the left main coronary artery).
  - I21.1 = Acute transmural myocardial infarction of inferior wall (STEMI involving the left anterior descending coronary artery).
  - I21.2 = Acute transmural myocardial infarction of other sites (STEMI involving other coronary artery of anterior wall).
  - I21.3 = Acute transmural myocardial infarction of unspecified site (STEMI involving inferior wall).
  - I21.4 = Acute subendocardial myocardial infarction (NSTEMI).
  - I21.9 = Acute myocardial infarction, unspecified.
• I22 = Subsequent myocardial infarction:
  -  I22.9 = Subsequent myocardial infarction of unspecified site.
  I25 = Chronic ischaemic heart disease.
  - I25.9 = Chronic ischaemic heart disease, unspecified.

Epidemiology

Prevalence

• ACS is a leading cause of morbidity and mortality worldwide.
• In South Africa, cardiovascular diseases are responsible for one in six deaths, with ACS being a significant contributor.
• Hospital admissions for ACS in South Africa are increasing, with a noticeable burden in urban areas due to lifestyle factors.

Age and Sex Distribution

• ACS predominantly affects older adults, with a higher incidence in males compared to females.
• Men typically present with ACS about 10 years earlier than women.

Regional Variations

• Higher prevalence in urban areas due to increased risk factors such as smoking, poor diet, and lack of physical activity.
• Rural areas may have lower incidence but higher case-fatality rates due to limited access to healthcare facilities.

Impact on Quality of Life

• ACS significantly impacts daily functioning and quality of life.
• Increased healthcare utilisation and costs due to recurrent hospitalisations and long-term management.
• Significant psychological impact, including increased risk of anxiety and depression post-ACS.

Risk Factors

Modifiable Risk Factors

• Smoking:
  - Strongly associated with increased risk of ACS.
• Hypertension:
  - Poorly controlled blood pressure is a major risk factor.
• Diabetes mellitus:
  - Doubles the risk of ACS due to associated vascular complications.
• Dyslipidaemia:
  - High LDL cholesterol and low HDL cholesterol levels contribute to atherosclerosis.
• Obesity:
  - Particularly central obesity increases the risk.
• Physical inactivity:
  - Sedentary lifestyle contributes to poor cardiovascular health.
• Diet:
  - Diets high in saturated fats, trans fats, and cholesterol increase risk.

Non-modifiable Risk Factors

• Age:
  - Risk increases with age, particularly after 45 years in men and 55 years in women.
• Sex:
  - Males are at higher risk; however, post-menopausal women have a similar risk to men.
• Family history:
  - Family history of premature cardiovascular disease increases risk.
• Genetic factors:
  - Specific genetic predispositions may contribute to higher risk.

Other Risk Factors

• Psychosocial factors:
  - Chronic stress, anxiety, and depression are linked to higher ACS risk.
• Chronic kidney disease:
  - Associated with accelerated atherosclerosis and increased cardiovascular risk.
• Autoimmune conditions:
  - Diseases like rheumatoid arthritis and lupus are associated with higher cardiovascular risk.

Emerging Risk Factors

• Inflammatory markers:
  - Elevated levels of CRP and other inflammatory markers are associated with higher risk.
• Sleep apnoea:
  - Associated with increased cardiovascular risk due to intermittent hypoxia and increased sympathetic activity.
• Air pollution:
  - Long-term exposure is linked to higher cardiovascular disease incidence.

Key Points

• Early recognition: Prompt identification and management of ACS symptoms are critical.
• Risk stratification: Use tools like GRACE score for risk assessment and management planning.
• Lifestyle interventions: Emphasise the importance of smoking cessation, healthy diet, regular exercise, and weight management.
• Pharmacotherapy: Ensure optimal medical therapy including antiplatelet agents, statins, ACE inhibitors, and beta-blockers.
• Monitoring and follow-up: Regular monitoring for complications and secondary prevention strategies to reduce recurrence.

Definition and Pathophysiology

Definition

Acute Coronary Syndrome (ACS)

• ACS refers to a spectrum of conditions associated with sudden, reduced blood flow to the heart muscle, encompassing:

Unstable Angina (UA)

• Characterised by new or worsening chest pain or discomfort that occurs at rest or with minimal exertion.

Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)

• Marked by myocardial necrosis without ST-segment elevation on ECG

ST-Segment Elevation Myocardial Infarction (STEMI)

• Defined by complete occlusion of a coronary artery, leading to significant myocardial injury and ST-segment elevation on ECG.

Diagnosis

• Based on clinical presentation, ECG changes, and elevated cardiac biomarkers (e.g., troponin levels).

Pathophysiology

Atherosclerosis and Plaque Rupture

• Atherosclerosis:
  - Chronic inflammatory disease is characterised by the accumulation of lipid-rich plaques in the coronary arteries.
• Plaque rupture/fissure:
  - Disruption of the fibrous cap of an atherosclerotic plaque exposes the lipid core to the bloodstream and triggers thrombus formation.
• Thrombus formation:
  - Platelet aggregation and activation of the coagulation cascade lead to thrombus formation, which can partially or completely occlude the coronary artery.

Ischaemia and Infarction

• Myocardial ischaemia:
  - Reduced blood flow to the myocardium due to arterial obstruction, resulting in oxygen deprivation.
• Myocardial infarction (MI):
  - Prolonged ischaemia leads to irreversible myocardial cell death. The extent of infarction depends on the duration of ischaemia and the size of the affected area.
• NSTEMI:
  - Partial thickness infarction, primarily involving the subendocardium.
• STEMI:
  - Full-thickness infarction, involving the entire myocardial wall.

Inflammatory Response

• Acute inflammation:  
  - Release of inflammatory mediators (e.g., cytokines, chemokines) following plaque rupture, contributing to further vascular injury and thrombus stability.  
• Chronic inflammation:  
  - Persistent low-grade inflammation contributes to plaque progression and vulnerability.  

Neurohumoral Activation

• Sympathetic nervous system:  
  - Activation leads to increased heart rate, blood pressure, and myocardial oxygen demand.
• Renin-angiotensin-aldosterone system (RAAS):  
  - Activation promotes vasoconstriction, sodium retention, and further increases blood pressure.  

Endothelial Dysfunction

• Nitric oxide (NO) deficiency:  
  - Reduced NO availability impairs vasodilation and promotes platelet aggregation and   adhesion.  
• Endothelin-1 overproduction:  
  - Increased levels of endothelin-1 lead to vasoconstriction and heightened vascular tone.  

Metabolic Dysregulation

• Insulin resistance:
  - Common in patients with ACS, contributes to endothelial dysfunction and increased atherogenicity.
• Dyslipidaemia:
  - Elevated LDL and reduced HDL levels promote atherosclerosis and plaque instability.

Genetic and Environmental Factors

• Genetic predisposition:
  - Family history of coronary artery disease (CAD) increases risk due to inherited genetic variations affecting lipid metabolism, inflammation, and coagulation pathways.
• Environmental influences:
  - Smoking, poor diet, physical inactivity, and stress are major modifiable risk factors.

Reperfusion Injury

• Reperfusion injury:
  - Paradoxical tissue damage occurs after the restoration of blood flow, primarily due to oxidative stress, inflammation, and calcium overload.

Key Points

• Prompt identification: Early recognition and treatment of ACS are critical to improving outcomes.
• Risk stratification: Use validated tools (e.g., TIMI, GRACE scores) for assessing risk and guiding management.
• Integrated care: Coordination between emergency, cardiology, and rehabilitation services to ensure comprehensive care.

Clinical Presentation

Symptoms

Unstable Angina (UA)

• Chest pain:
  - New onset or worsening chest discomfort, often described as pressure, squeezing, or burning, occurring at rest or with minimal exertion.
• Radiating pain:
  - Discomfort may radiate to the shoulders, arms, neck, jaw, or back.
• Shortness of breath:
  - Dyspnoea often accompanies chest pain, particularly in elderly patients.
• Nausea and vomiting:
  - Common, particularly in women and elderly patients.
• Diaphoresis:
  - Excessive sweating is often associated with pain.
• Fatigue:
  - Unusual tiredness, especially in women and elderly patients.
• Light-headedness:
  - Feeling faint or dizzy without loss of consciousness.

Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)

• Chest pain:
  - Severe, persistent pain similar to that in UA but more intense and prolonged.
• Radiating pain:
  - Pain radiates similarly as in UA but can be more widespread.
• Dyspnoea:
  - More pronounced due to myocardial damage.
• Nausea and vomiting:
  - More frequent and severe compared to UA.
• Diaphoresis:
  - Profuse sweating is indicative of a sympathetic response.
• Palpitations:
  - Noticeable heartbeats that may feel irregular or rapid.
• Fatigue:
  - Severe and persistent tiredness due to myocardial injury.
• Syncope:
  - Temporary loss of consciousness or fainting due to reduced cardiac output.

ST-Segment Elevation Myocardial Infarction (STEMI)

• Chest pain:
  - Intense, crushing chest pain is often described as the worst ever experienced, lasting more than 20 minutes.
• Radiating pain:
  - Pain radiates to the same areas as in UA and NSTEMI but with greater intensity.
• Dyspnoea:
  - Severe shortness of breath due to significant myocardial damage.
• Nausea and vomiting:
  - Severe and often accompanied by abdominal pain.
• Diaphoresis:
  - Profuse sweating is a classic sign of STEMI.
• Palpitations:
  - Irregular and rapid heartbeats are more common.
• Fatigue:
  - Debilitating tiredness, often accompanied by a sense of impending doom.
• Syncope:
  - More frequent due to severe reduction in cardiac output.
• Anxiety:
  - Extreme anxiety or a feeling of impending doom.

Signs

General Examination

• Vital signs:
  - Elevated heart rate (tachycardia), high blood pressure (hypertension) or low blood pressure (hypotension), and tachypnoea.
• Skin:
  - Pale, cool, and clammy skin due to sympathetic activation.

Cardiovascular Examination

• Heart sounds:
  - S3 and/or S4 gallop, new murmur indicating mitral regurgitation or ventricular septal defect.
• Jugular venous pressure (JVP):
  - Elevated JVP may indicate right heart failure.
• Peripheral pulses:
  - Weak or absent pulses in severe cases.

Respiratory Examination

• Crackles:
  - Pulmonary crackles or rales indicating pulmonary congestion or heart failure.

Diagnostic Criteria

Unstable Angina (UA)

• ECG changes:
  - ST-segment depression, transient ST-segment elevation, or T-wave inversion without persistent elevation.
• Cardiac biomarkers:
  - Normal levels of cardiac troponins.

Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)

• ECG changes:
  - Similar to UA with no persistent ST-segment elevation.
• Cardiac biomarkers:
  - Elevated troponin levels indicating myocardial necrosis.

ST-Segment Elevation Myocardial Infarction (STEMI)

• ECG changes:
  - Persistent ST-segment elevation in at least two contiguous leads or new left bundle branch block (LBBB).
• Cardiac biomarkers:
  - Significantly elevated troponin levels confirming myocardial necrosis.

Additional Diagnostic Considerations

Risk Stratification

• Scoring systems:
  - Use of tools like the GRACE or TIMI scores to evaluate risk and guide treatment strategies.

Imaging Studies

• Echocardiography:
  - Assessment of ventricular function and detection of complications such as mitral regurgitation or ventricular septal defect.
• Coronary angiography:
  - Gold standard for assessing coronary anatomy and guiding revascularisation.

Functional Impact

• Quality of life:
  - ACS significantly impacts daily functioning, with long-term consequences on physical and mental health.
• Work and social activities:
  - Patients may experience reduced productivity and withdrawal from social interactions.

Patient-Reported Outcomes

• Symptom assessment:
  - Utilisation of validated scales (e.g., Seattle Angina Questionnaire) to monitor symptoms and treatment response.
• Symptom diaries:
  - Patients may keep diaries to track changes in symptoms and identify triggers.

Key Points

• Early detection: Prompt recognition of symptoms and signs is crucial for effective management.
• Comprehensive assessment: Include detailed history, physical examination, and appropriate use of diagnostic tools.
• Patient education: Educate patients on recognising symptoms and seeking timely medical help.

Differential Diagnosis

Conditions to Consider

Gastroesophageal Reflux Disease (GERD)

• Symptoms:
  - Retrosternal burning pain, often worsened by lying down or after meals.
• Differentiation:
  - Pain usually relieved by antacids and not associated with exertion.

Pericarditis

• Symptoms:
  - Sharp, pleuritic chest pain that improves when sitting up and leaning forward.
• Differentiation:
  - Pericardial friction rub on auscultation, diffuse ST-segment elevation on ECG.

Pulmonary Embolism (PE)

• Symptoms:
  - Sudden onset of pleuritic chest pain, dyspnoea, and haemoptysis.
• Differentiation:
  - Tachycardia, hypoxia, and positive D-dimer test. Confirmed by CT pulmonary angiography.

Aortic Dissection

• Symptoms:
  - Sudden, severe tearing or ripping chest pain radiating to the back.
• Differentiation:
  - Differential blood pressure in arms, widened mediastinum on chest X-ray, confirmed by CT angiography.

Costochondritis

• Symptoms:
  - Localised anterior chest wall pain, often reproducible on palpation.
• Differentiation:
  - Pain is musculoskeletal in nature, no ECG changes.

Pneumonia

• Symptoms:
  - Pleuritic chest pain, fever, cough, and sputum production.
• Differentiation:
  - Consolidation on chest X-ray, elevated white cell count.

Pneumothorax

• Symptoms:
  - Sudden onset of unilateral pleuritic chest pain and dyspnoea.
• Differentiation:
  - Decreased breath sounds on the affected side, hyperresonance on percussion, confirmed by chest X-ray.

Peptic Ulcer Disease (PUD)

• Symptoms:
  - Epigastric pain that may be relieved by eating or antacids.
• Differentiation:
  - Endoscopic evidence of ulcers, pain unrelated to exertion.

Cholecystitis

• Symptoms:
  - Right upper quadrant pain radiating to the right shoulder, often after fatty meals.
• Differentiation:
  - Positive Murphy's sign, ultrasound evidence of gallstones or inflammation.

Panic Disorder

• Symptoms:
  - Sudden episodes of intense fear or discomfort, palpitations, sweating, and a sense of impending doom.
• Differentiation:
  - Episodes typically last for minutes, no ECG changes, normal cardiac biomarkers.

Key Differentiators

Gastroesophageal Reflux Disease (GERD)

• Differentiation:
  - Relief with antacids, correlation with meals, absence of ECG changes or elevated cardiac biomarkers.

Pericarditis

• Differentiation:
  - Positional pain relief, presence of pericardial friction rub, diffuse ST-segment elevation on ECG without reciprocal changes.

Pulmonary Embolism (PE)

• Differentiation:
  - Risk factors (e.g., recent surgery, immobility), hypoxia, positive D-dimer, confirmation by CT pulmonary angiography.

Aortic Dissection

• Differentiation:
  - Severe tearing pain, differential blood pressure in arms, widened mediastinum on chest X-ray, confirmed by CT angiography.

Costochondritis

• Differentiation:
  - Reproducible pain on palpation of the chest wall, absence of ECG changes or elevated cardiac biomarkers.

Pneumonia

• Differentiation:
  - Fever, productive cough, consolidation on chest X-ray, elevated white cell count.

Pneumothorax

• Differentiation:
  - Unilateral decreased breath sounds, hyperresonance on percussion, confirmed by chest X-ray.

Peptic Ulcer Disease (PUD)

• Differentiation:
  - Epigastric pain relieved by food or antacids, endoscopic evidence of ulcers.

Cholecystitis

• Differentiation:
  - Positive Murphy's sign, ultrasound evidence of gallstones or gallbladder inflammation.

Panic Disorder

• Differentiation:
  - Sudden onset, short duration, absence of ECG changes or elevated cardiac biomarkers.

Key Points

• Comprehensive assessment: Ensure thorough history and physical examination to distinguish ACS from other conditions.
• Use of diagnostic tools: ECG, cardiac biomarkers, and imaging studies are crucial for accurate diagnosis.
• Multidisciplinary approach: Collaborate with specialists (e.g., cardiologists, radiologists) for complex cases.

Diagnostic Tests

Initial Tests

Electrocardiogram (ECG)

• Purpose:
  - First-line test to assess for myocardial ischaemia or infarction.
• Findings:
  - ST-Segment Elevation: Indicates STEMI.
  - ST-Segment Depression or T-Wave Inversion: Suggests NSTEMI or unstable angina.
  - New Left Bundle Branch Block (LBBB): Considered equivalent to STEMI.
• Serial ECGs:
  - Recommended if initial ECG is non-diagnostic but clinical suspicion remains high.

Blood Tests

• Cardiac Biomarkers:
  • Troponins (T and I):
    - Elevated levels indicate myocardial necrosis.
  • Creatine kinase-MB (CK-MB):
    - Less specific but can be used alongside troponins.
• Full blood count (FBC):
  - To identify anaemia or infection that may complicate ACS.
• Electrolytes and renal function:
  • Electrolytes (Na+, K+, Cl-, HCO3-):
    - Imbalances can exacerbate cardiac conditions.
• Renal function tests (Urea, Creatinine):
  - Assess kidney function, particularly important for medication dosing.
• Liver function tests:
  - To rule out hepatic causes of symptoms and assess baseline liver function before initiating treatment.
• Lipid profile:
  - Baseline assessment for secondary prevention measures.

Advanced Tests

Imaging Studies

• Chest X-ray:
  - Purpose: To rule out other causes of chest pain such as pneumonia, pneumothorax, or aortic dissection.
  - Findings: Cardiomegaly, pulmonary congestion, or other abnormalities.
• Echocardiography:
  - Purpose: To evaluate cardiac structure and function.
  - Findings: Wall motion abnormalities, ejection fraction, and complications such as mitral regurgitation.
• Coronary angiography:
  - Purpose: Gold standard for identifying coronary artery blockages.
  - Indications: High-risk patients, confirmed STEMI, or persistent symptoms despite medical therapy.
• Cardiac CT and MRI:
  - Purpose: Non-invasive imaging to assess coronary arteries and myocardial tissue.
  - Indications: Ambiguous cases where initial tests are inconclusive.

Other Tests

Stress Testing

• Exercise stress test:
  - To assess functional capacity and induce ischaemia for evaluation.
• Pharmacologic stress test:
  - For patients unable to exercise, using agents like adenosine or dobutamine.

Nuclear Imaging (SPECT, PET)

• Purpose: To evaluate myocardial perfusion and viability.
• Indications: Patients with intermediate risk or inconclusive stress test results.

Biomarkers and Genetic Testing

Inflammatory Markers

• C-reactive protein (CRP):
  - Elevated in systemic inflammation, associated with higher cardiovascular risk.
• Interleukin-6 (IL-6):
  - Another marker for inflammation, often elevated in ACS.

Genetic Testing

• Pharmacogenomic testing:
  - Identifies genetic variations affecting drug metabolism and response, guiding personalised treatment plans.

Additional Diagnostic Considerations

Screening for Substance Use Disorders

• Drug and alcohol testing:
  - Identifies substances that may contribute to ACS symptoms or complicate treatment.

Hormonal Assessments

• Cortisol levels:
  - Assesses for hyperactivity of the HPA axis, which may be elevated in stress states.
• Sex hormones:
  - Evaluates hormonal imbalances, particularly in perimenopausal and postmenopausal women.

Psychiatric Evaluation

• Comprehensive assessment:
  - Performed by a psychiatrist to rule out anxiety or panic disorders presenting with chest pain.

Clinical Pitfalls

• Repeat evaluations: Regular follow-up assessments are crucial, particularly if initial tests are inconclusive.
• Early and accurate diagnosis: Ensures timely intervention, reducing the risk of complications and improving outcomes.
• Multidisciplinary approach: Collaboration with cardiologists, emergency physicians, and other specialists ensures comprehensive care.
• Consideration of comorbidities: Always assess for comorbid medical conditions that can impact ACS management and outcomes.
• Holistic view: Consider lifestyle factors, including diet, physical activity, and stress management, in the diagnostic process.

Management

First-line Therapy

Pharmacological Therapy

Antiplatelet Agents

• Aspirin:
  - Dose: 162-325 mg loading dose, then 81-162 mg daily.
  - Action: Inhibits platelet aggregation, reducing thrombus formation.
• P2Y12 inhibitors:
  • Clopidogrel:
    - Dose: 300-600 mg loading dose, then 75 mg daily.
  • Ticagrelor:
    - Dose: 180 mg loading dose, then 90 mg twice daily.
  • Prasugrel:
    - Dose: 60 mg loading dose, then 10 mg daily.

Anticoagulants

• Unfractionated heparin (UFH):
  - Dose: Initial bolus of 60-70 units/kg (maximum 5000 units), followed by an infusion of 12-15 units/kg/hour.
• Low molecular weight heparin (LMWH):
  • Enoxaparin:
    - Dose: 1 mg/kg subcutaneously every 12 hours.
• Direct oral anticoagulants (DOACs):
  • Rivaroxaban:
    - Dose: 2.5 mg twice daily in combination with aspirin and clopidogrel (for selected patients).

Beta-Blockers

• Metoprolol:
  - Dose: 25-50 mg orally every 6-12 hours, titrated based on heart rate and blood pressure.
  - Action: Reduces myocardial oxygen demand by lowering heart rate and contractility.

Nitrates

• Sublingual nitroglycerin:
  - Dose: 0.3-0.6 mg every 5 minutes as needed for chest pain (maximum 3 doses).
• Intravenous nitroglycerin:
  - Dose: 5-10 mcg/min, titrated to relief of chest pain or blood pressure response.

Statins

• Atorvastatin:
  - Dose: 40-80 mg daily.
  - Action: Reduces LDL cholesterol, stabilises plaques, and has anti-inflammatory effects.

Angiotensin-Converting Enzyme (ACE) Inhibitors

• Ramipril:
  - Dose: 2.5-5 mg daily.
  - Action: Reduces blood pressure, myocardial oxygen demand, and ventricular remodelling.

Calcium Channel Blockers (For patients intolerant to beta-blockers)

• Amlodipine:
  - Dose: 5-10 mg daily.
  - Action: Reduces myocardial oxygen demand and controls hypertension.

Non-Pharmacological Therapy

Percutaneous Coronary Intervention (PCI)

• Indication:
  - Preferred treatment for STEMI and high-risk NSTEMI.
• Procedure:
  - Involves angioplasty and stent placement to restore coronary blood flow.

Coronary Artery Bypass Grafting (CABG)

• Indication:
  - For patients with multivessel disease, left main coronary artery disease, or those not suitable for PCI.
• Procedure:
  - Surgical revascularisation using grafts to bypass blocked coronary arteries.

Lifestyle Modifications

Smoking Cessation

• Counselling and pharmacotherapy:
  - Nicotine replacement therapy, bupropion, or varenicline.

Diet

• Heart-healthy diet:
  - Rich in fruits, vegetables, whole grains, and lean proteins.

Exercise

• Regular physical activity:
  - At least 150 minutes of moderate-intensity exercise per week.

Weight Management

• Achieve and maintain a healthy weight:
  - BMI between 18.5 and 24.9.

Second-line Therapy

Combination Therapy

Dual Antiplatelet Therapy (DAPT)

• Combination:
  - Aspirin and a P2Y12 inhibitor for 12 months post-ACS.

Triple Therapy

• Combination:
  - For selected patients with high thrombotic risk, combining aspirin, P2Y12 inhibitor, and anticoagulant.

Invasive Strategies

Recurrent Ischaemia

• Repeat PCI or CABG:
  - For patients with recurrent symptoms or complications post-initial intervention.

Left Ventricular Assist Devices (LVADs)

• Indication:
  - For patients with severe heart failure not responsive to medical therapy.

Referral

Indications for Specialist Referral

• Cardiologist:
  - For complex cases requiring advanced intervention or persistent symptoms despite first-line therapy.
• Cardiothoracic surgeon:
  - For patients indicated for CABG or other surgical interventions.
• Dietitian:
  - For dietary counselling and management of comorbid conditions like diabetes or hyperlipidaemia.

Monitoring

Regular Follow-up

• Clinical evaluation:
  - Monitor response to treatment and adjust medications as necessary.
• Cardiac biomarkers:
  - Regular checks in hospital settings to assess ongoing myocardial damage.
• Electrolytes and renal function:
  - Regular monitoring, especially for patients on ACE inhibitors, ARBs, or diuretics.
• Lipid profile:
  - Periodic assessment to ensure lipid targets are met.

Long-term Management

Maintenance Therapy

• Continued use of antiplatelets, statins, beta-blockers, and ACE inhibitors as per guidelines.

Lifestyle Modifications

• Ongoing encouragement and support for healthy lifestyle changes.

Cardiac Rehabilitation

• Structured programme to improve cardiovascular health post-ACS.

Follow-up

Routine Follow-ups

• Scheduled appointments:
  - Regular visits to monitor progress, manage medications, and assess adherence.
• Symptom monitoring:
  - Utilise validated scales to track symptom changes and treatment efficacy.

Patient and Family Involvement

• Education: Provide comprehensive education on medication adherence, lifestyle modifications, and recognising symptoms of recurrence.
• Support: Involve family members in care plans for additional support and understanding.

Medications

Drug Name

Antiplatelet Agents

• Aspirin
• Clopidogrel
• Ticagrelor
• Prasugrel

Anticoagulants

• Unfractionated Heparin (UFH)
• Low Molecular Weight Heparin (LMWH)
• Rivaroxaban

Beta-Blockers

• Metoprolol
• Atenolol

Nitrates

• Sublingual Nitroglycerin
• Intravenous Nitroglycerin

Statins

• Atorvastatin
• Rosuvastatin

Angiotensin-Converting Enzyme (ACE) Inhibitors

• Ramipril
• Lisinopril

Calcium Channel Blockers

• Amlodipine
• Diltiazem

Posology (Dosage)

Drug	Posology
Antiplatelet Agents
Aspirin	162-325 mg loading dose, then 81-162 mg daily. (Action: Inhibits platelet aggregation, reducing thrombus formation.)
Clopidogrel	300-600 mg loading dose, then 75 mg daily.
Ticagrelor	180 mg loading dose, then 90 mg twice daily.
Prasugrel	60 mg loading dose, then 10 mg daily.
Anticoagulants
Unfractionated heparin (UFH)	Initial bolus of 60-70 units/kg (maximum 5000 units), followed by an infusion of 12-15 units/kg/hour.
Low molecular weight heparin (LMWH) – Enoxaparin	1 mg/kg subcutaneously every 12 hours.
Rivaroxaban	2.5 mg twice daily in combination with aspirin and clopidogrel (for selected patients).
Beta-Blockers
Metoprolol	25-50 mg orally every 6-12 hours, titrated based on heart rate and blood pressure.
Atenolol	50-100 mg daily.
Nitrates
Sublingual nitroglycerin	0.3-0.6 mg every 5 minutes as needed for chest pain (maximum 3 doses).
Intravenous nitroglycerin	5-10 mcg/min, titrated to relief of chest pain or blood pressure response.
Statins
Atorvastatin	40-80 mg daily.
Rosuvastatin	20-40 mg daily.
Angiotensin-Converting Enzyme (ACE) Inhibitors
Ramipril	2.5-5 mg daily.
Lisinopril	10-20 mg daily.
Calcium Channel Blockers
Amlodipine	5-10 mg daily.
Diltiazem	120-360 mg daily.

Side Effects

Antiplatelet Agents

• Aspirin:
  - Common: Gastrointestinal bleeding, dyspepsia.
• Clopidogrel:
  - Common: Bleeding, rash.
• Ticagrelor:
  - Common: Dyspnoea, bleeding.
• Prasugrel:
  - Common: Bleeding, hypertension.

Anticoagulants

• Unfractionated Heparin (UFH):
  - Common: Bleeding, thrombocytopenia.
• Low Molecular Weight Heparin (LMWH):
  - Common: Bleeding, injection site reactions.
• Rivaroxaban:
  - Common: Bleeding, anaemia.

Beta-Blockers

• Metoprolol:
  - Common: Bradycardia, hypotension, fatigue.
• Atenolol:
  - Common: Bradycardia, cold extremities, fatigue.

Nitrates

• Sublingual nitroglycerin:
  - Common: Headache, hypotension.
• Intravenous nitroglycerin:
  - Common: Headache, hypotension, tachycardia.

Statins

• Atorvastatin:
  - Common: Myopathy, elevated liver enzymes.
• Rosuvastatin:
  - Common: Myalgia, elevated liver enzymes.

Angiotensin-Converting Enzyme (ACE) Inhibitors

• Ramipril:
  - Common: Cough, hyperkalaemia, renal impairment.
• Lisinopril:
  - Common: Cough, hyperkalaemia, hypotension.

Calcium Channel Blockers

• Amlodipine:
  - Common: Peripheral oedema, headache.
• Diltiazem:
  - Common: Bradycardia, peripheral oedema.

Interactions

Antiplatelet Agents

• Aspirin:
  - NSAIDs: Increased risk of gastrointestinal bleeding.
  - Anticoagulants: Increased risk of bleeding.
• Clopidogrel:
  - Proton pump inhibitors (PPIs): Reduced antiplatelet effect.
• Ticagrelor:
  - Strong CYP3A4 inhibitors: Increased plasma concentration.
• Prasugrel:
  - NSAIDs: Increased risk of bleeding.

Anticoagulants

• Unfractionated heparin (UFH):
  - Antiplatelets: Increased risk of bleeding.
• Low molecular weight heparin (LMWH):
  - Antiplatelets: Increased risk of bleeding.
• Rivaroxaban:
  - Antiplatelets: Increased risk of bleeding.

Beta-Blockers

• Metoprolol:
  - Calcium channel blockers: Additive bradycardia.
• Atenolol:
  - Calcium channel blockers: Additive bradycardia.

Nitrates

• Sublingual nitroglycerin:
  - Phosphodiesterase Inhibitors: Severe hypotension.
• Intravenous nitroglycerin:
  - Phosphodiesterase inhibitors: Severe hypotension.

Statins

• Atorvastatin:
  - Strong CYP3A4 inhibitors: Increased risk of myopathy.
• Rosuvastatin:
  - Cyclosporine: Increased risk of myopathy.

Angiotensin-Converting Enzyme (ACE) Inhibitors

• Ramipril:
  - Potassium-sparing diuretics: Hyperkalaemia.
• Lisinopril:
  - Potassium-sparing diuretics: Hyperkalaemia.

Calcium Channel Blockers

• Amlodipine:
  - Beta-blockers: Additive hypotensive effect.
• Diltiazem:
  - Beta-blockers: Additive hypotensive effect.

Key Points

• Regular monitoring: Essential for detecting side effects and ensuring medication efficacy.
• Patient education: Emphasise adherence to medication regimens and awareness of potential side effects.
• Drug interactions: Be vigilant about potential interactions, especially in patients on multiple medications.

Complications

Acute Complications

Heart Failure

• Description: Acute left or right ventricular dysfunction due to myocardial injury.
• Management: Requires urgent diuretics, inotropes, and sometimes mechanical support (e.g., intra-aortic balloon pump).

Cardiogenic Shock

• Description: Severe reduction in cardiac output leading to hypotension and organ hypoperfusion.
• Management: Requires immediate vasopressors, inotropes, and mechanical circulatory support (e.g., ECMO).

Arrhythmias

• Description: Includes ventricular fibrillation, ventricular tachycardia, atrial fibrillation, and bradyarrhythmias.
• Management: Antiarrhythmic drugs, electrical cardioversion, or pacing depending on the type and severity.

Mechanical Complications

• Papillary muscle rupture: Leads to acute mitral regurgitation.
• Ventricular septal rupture: Causes left-to-right shunt.
• Free wall rupture: Often fatal, leading to cardiac tamponade.
• Management: Requires urgent surgical intervention.

Pericarditis

• Description: Inflammation of the pericardium presenting with chest pain and pericardial rub.
• Management: Anti-inflammatory medications such as NSAIDs or colchicine.

Thromboembolism

• Description: Includes left ventricular thrombus formation and systemic embolism.
• Management: Anticoagulation therapy is indicated.

Chronic Complications

Heart Failure

• Description: Progressive ventricular dysfunction leading to chronic heart failure.
• Management: Long-term use of ACE inhibitors, beta-blockers, diuretics, and aldosterone antagonists.

Recurrent Myocardial Infarction

• Description: Increased risk of subsequent myocardial infarction.
• Management: Intensive secondary prevention with lifestyle modifications, medications, and revascularisation if indicated.

Chronic Kidney Disease

• Description: Progressive renal impairment due to decreased cardiac output and nephrotoxic medications.
• Management: Optimise heart failure treatment and monitor renal function regularly.

Depression and Anxiety

• Description: Psychological impact post-ACS, including persistent anxiety and depression.
• Management: Psychotherapy, antidepressants, and support groups.

Atrial Fibrillation

• Description: Persistent arrhythmia increasing the risk of stroke and heart failure.
• Management: Anticoagulation, rate or rhythm control strategies.

Post-Infarction Syndrome (Dressler's Syndrome)

• Description: Late pericarditis occurring weeks to months after myocardial infarction.
• Management: NSAIDs or corticosteroids for inflammation.

Ventricular Aneurysm

• Description: Thinning and dilation of the ventricular wall at the infarct site.
• Management: Medical therapy for heart failure symptoms; surgical resection in selected cases.

Mitral Regurgitation

• Description: Valve dysfunction due to papillary muscle or chordae tendineae damage.
• Management: Medical management of heart failure; surgical repair or replacement if severe.

Preventive Measures

Prophylactic Interventions

• Regular monitoring: Early detection of complications through regular follow-up and diagnostic testing.
• Risk factor management: Control of hypertension, diabetes, dyslipidaemia, and smoking cessation.

Patient Education

• Treatment adherence: Emphasise the importance of taking medications as prescribed.
• Symptom recognition: Educate patients on recognising early signs of complications and seeking timely medical help.

Lifestyle Modifications

• Physical activity: Encourage regular exercise tailored to the patient’s capacity.
• Healthy diet: Advocate for a diet low in saturated fats, cholesterol, and sodium.
• Stress management: Promote techniques such as mindfulness, yoga, and support groups.

Regular Follow-up

• Clinical visits: Regular appointments to monitor progress and adjust treatment.
• Diagnostic tests: Use of validated tools to assess cardiac function and detect early signs of complications.

Impact on Quality of Life

Daily Functioning

• Impairment: Chronic complications significantly impair daily activities and reduce quality of life.
• Support systems: Effective treatment and strong support systems are critical for improving functionality.

Increased Healthcare Utilisation

• Frequent interventions: Regular medical visits, potential hospitalisations, and emergency care.
• Comprehensive care plans: Essential to minimise acute episodes and manage chronic conditions effectively.

Economic Burden

• Costs: Direct costs of treatment and indirect costs due to loss of productivity.
• Economic factors: Addressing economic factors is crucial for long-term management and adherence to treatment.

Psychological Effects

• Chronic stress: Persistent anxiety and feelings of hopelessness are common.
• Integrated care: Addressing both physical and mental health aspects is essential for overall well-being.

Patient Education

Lifestyle Modifications

Diet and Nutrition

• Heart-healthy diet:
  - Emphasise a diet rich in fruits, vegetables, whole grains, and lean proteins.
  - Limit intake of saturated fats, trans fats, cholesterol, and sodium.
  - Encourage consumption of omega-3 fatty acids found in fish, nuts, and seeds.
• Hydration:
  - Drink plenty of water and avoid excessive consumption of caffeinated or sugary drinks.

Physical Activity

• Regular exercise:
  - Engage in at least 30 minutes of moderate-intensity exercise most days of the week.
  - Activities such as walking, cycling, swimming, and yoga can improve cardiovascular health and reduce stress.

Smoking Cessation

• Quit smoking:
  - Strongly encourage cessation of smoking and provide resources for support.
  - Discuss pharmacotherapy options like nicotine replacement therapy, bupropion, or varenicline.

Alcohol Consumption

• Limit alcohol intake:
  - Advise moderation in alcohol consumption; excessive drinking can exacerbate heart conditions.

Weight Management

• Maintain a healthy weight:
  - Encourage a balanced diet and regular physical activity to achieve and maintain a healthy weight.

Sleep Hygiene

• Consistent sleep schedule:
  - Establish regular sleep patterns by going to bed and waking up at the same time each day.
  - Create a restful sleep environment free of screens and disturbances.
  - Avoid stimulants like caffeine and heavy meals close to bedtime.

Preventive Measures

Stress Management

• Relaxation techniques:
  - Practise relaxation methods such as deep breathing, meditation, or progressive muscle relaxation.
  - Identify stressors and develop coping strategies with the help of support systems.

Routine and Structure

• Daily routine:
  - Establish a structured daily schedule that includes time for work, rest, and leisure activities.
  - Balance daily demands to prevent stress and burnout.

Social Support

• Stay connected:
  - Maintain regular contact with family and friends.
  - Join support groups for individuals with heart conditions to share experiences and coping strategies.

Support Resources

Patient Support Groups

• Local and online groups:
  - Participate in support groups for individuals with heart conditions.
  - These groups provide emotional support and practical advice.

Educational Materials

• Access reliable information:
  - Provide patients with brochures, websites, and mobile apps that offer guidance on heart health, symptoms, and management.

Counselling and Therapy

• Mental health support:
  - Regular sessions with a mental health professional can help manage stress and anxiety related to heart conditions.
  - Cognitive behavioural therapy (CBT) and other therapeutic approaches can be beneficial.

Medication Adherence

Importance of Medication

• Take medications as prescribed:
  - Emphasise the importance of adhering to prescribed medication regimens.
  - Discuss potential side effects and strategies to manage them, highlighting the risks of abrupt discontinuation.

Medication Diary

• Track medication:
  - Encourage keeping a medication diary to monitor dosages and effects.
  - Use reminders and pill organisers to ensure consistent medication intake.

Symptom Tracking

Symptom Diary

• Record symptoms:
  - Encourage patients to keep a diary of symptoms, mood changes, and potential triggers.
  - Symptom tracking can help adjust treatment plans and identify patterns.

Communication with Healthcare Providers

Regular Check-ins

• Open communication:
  - Advise patients to maintain regular contact with their healthcare team.
  - Routine check-ins help monitor symptom progression and treatment efficacy.

Reporting Symptoms

• Prompt reporting:
  - Encourage patients to report any new or worsening symptoms immediately.
  - Discuss any side effects of medications to adjust treatment as necessary.

Holistic Approaches

Complementary Therapies

• Explore alternatives:
  - Discuss complementary therapies such as acupuncture or mindfulness, ensuring they are coordinated with conventional medical treatments to avoid interactions.
  - Emphasise the importance of a balanced approach that includes medical treatments and lifestyle modifications.

Long-Term Management

Ongoing Care

• Continuous management:
  - Educate patients that managing heart conditions requires ongoing care and monitoring.
  - Set realistic expectations about symptom control and the potential need for long-term lifestyle adjustments.

Active Role in Care

• Empower patients:
  - Encourage patients to take an active role in their care and decision-making process.
  - Provide tools and resources to empower patients in managing their condition effectively.

References and Guidelines

Key References

• Kiefer T. Acute Coronary Syndromes Without ST-Segment Elevation. In: Papadakis MA, McPhee SJ, Rabow MW, editors. Current Medical Diagnosis & Treatment 2024. New York: McGraw-Hill; 2024.
• Kiefer T. Acute Myocardial Infarction with ST-Segment Elevation. In: Papadakis MA, McPhee SJ, Rabow MW, editors. Current Medical Diagnosis & Treatment 2024. New York: McGraw-Hill; 2024.
• Boyle AJ. Acute Myocardial Infarction. In: Crawford MH, editor. Current Diagnosis & Treatment: Cardiology, 6th ed. New York: McGraw-Hill; 2023.

Clinical Guidelines

• National Institute for Health and Care Excellence (NICE). Acute Coronary Syndromes (NG185):
  - Provides comprehensive guidelines for the diagnosis, treatment, and management of acute coronary syndromes. Emphasises rapid assessment, risk stratification, and evidence-based therapeutic interventions (NICE acute-coronary-syn…).
• American College of Cardiology (ACC)/American Heart Association (AHA). 2014 AHA/ACC Guideline for the Management of Patients with Non–ST-Elevation Acute Coronary Syndromes:
  - Outlines evidence-based recommendations for the management of patients with non–ST-elevation acute coronary syndromes. Focuses on early risk assessment, antithrombotic therapy, and revascularisation strategies.
• European Society of Cardiology (ESC). ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting with ST-Segment Elevation:
  - Provides detailed recommendations for the management of ST-segment elevation myocardial infarction (STEMI). Includes guidelines on reperfusion therapy, antithrombotic management, and secondary prevention.
• South African Heart Association (SA Heart). Guidelines for the Management of Acute Coronary Syndromes in South Africa:
  - Offers specific recommendations tailored to the South African healthcare context, focusing on resource-sensitive approaches to the management of acute coronary syndromes.

Notes for HCPs

Clinical Pearls and Pitfalls

Ensure Patient Compliance with Treatment

• Patient education: Educate patients on the importance of adhering to prescribed medications, including antiplatelet agents, beta-blockers, statins, and ACE inhibitors.
• Clear instructions: Provide clear instructions on medication schedules, potential side effects, and the necessity of not abruptly stopping medications without consulting a healthcare provider.

Monitor for Drug Interactions

• Regular review: Regularly review patients' medication lists to identify potential interactions, particularly with antiplatelet agents and anticoagulants.
• Caution with polypharmacy: Be cautious with polypharmacy, especially in patients with comorbid conditions such as diabetes or renal impairment.

Recognise and Manage Comorbid Conditions

• Screening: Screen for and address comorbid conditions such as diabetes, hypertension, and chronic kidney disease.
• Tailored treatment: Consider the impact of chronic medical conditions on heart health and tailor treatment plans accordingly.

Evaluate and Address Lifestyle Factors

• Physical activity: Encourage patients to engage in regular physical activity appropriate to their capacity.
• Healthy diet: Promote a heart-healthy diet rich in fruits, vegetables, whole grains, and lean proteins.
• Smoking cessation: Strongly advocate for smoking cessation and provide resources for support.

Be Vigilant for Acute Symptoms and Complications

• Prompt intervention: Promptly address symptoms such as chest pain, dyspnoea, or palpitations, which may require urgent intervention.
• Monitoring: Monitor for signs of complications such as heart failure, arrhythmias, and thromboembolic events.

Customise Treatment Plans

• Individualised approach: Tailor pharmacological treatments based on individual patient factors, including age, comorbid conditions, and previous response to medications.
• Adjust dosages carefully: Monitor for therapeutic effectiveness and adverse effects, adjusting dosages as necessary.

Educate Patients about Prevention

• Preventive measures: Discuss preventive measures, including lifestyle modifications and adherence to treatment plans.
• Early recognition: Provide information on recognising early signs of ACS recurrence and seeking timely medical intervention.

Consider the Use of Non-Pharmacological Interventions

• Cardiac rehabilitation: Encourage participation in cardiac rehabilitation programmes to enhance recovery and reduce the risk of future cardiac events.
• Support systems: Promote the use of support groups and educational programmes to enhance coping strategies and improve quality of life.

Screen for and Manage Psychological Comorbidities

• Mental health: Recognise that ACS can significantly impact quality of life and lead to secondary issues such as anxiety and depression.
• Referrals: Consider referrals to mental health professionals for comprehensive care.

Set Realistic Expectations

• Long-term commitment: Educate patients that managing ACS often requires a long-term commitment to treatment and lifestyle adjustments.
• Ongoing follow-ups: Emphasise the importance of ongoing follow-ups and preventive measures to maintain stability and prevent relapse.

Follow-Up and Monitoring

• Regular appointments: Schedule regular follow-up appointments to monitor progress, adjust treatment plans, and provide ongoing support.
• Assessment tools: Use validated assessment tools to track symptom changes and treatment effectiveness over time.

Clinical Highlights

• Recognise and diagnose acute coronary syndromes (ACS) through thorough clinical assessment, ECG interpretation, and measurement of cardiac biomarkers.
• Consider differential diagnoses and rule out other causes of chest pain such as gastroesophageal reflux disease, pericarditis, pulmonary embolism, and aortic dissection.
• Initiate treatment promptly with antiplatelet agents (aspirin and P2Y12 inhibitors), anticoagulants (heparin or LMWH), beta-blockers, nitrates, and statins.
• Tailor pharmacological therapy based on individual patient factors, comorbidities, and risk stratification using tools like the TIMI or GRACE scores.
• Regularly assess treatment efficacy and side effects, adjusting dosages as needed, and considering revascularisation procedures such as PCI or CABG for high-risk patients.
• Monitor for complications such as heart failure, arrhythmias, cardiogenic shock, and recurrent myocardial infarction.
• Promote lifestyle modifications including smoking cessation, regular physical activity, a heart-healthy diet, weight management, and stress reduction techniques.
• Emphasise the importance of medication adherence, discussing potential side effects and strategies to manage them, and warning against abrupt discontinuation without medical advice.
• Screen for and manage comorbid conditions such as diabetes, hypertension, and chronic kidney disease, integrating treatment plans accordingly.
• Encourage participation in cardiac rehabilitation programmes and support groups, offering educational materials on ACS and its management.
• Promptly address severe symptoms and complications, ensuring regular follow-ups and preventive measures to minimise the risk of recurrence.
• Incorporate non-pharmacological interventions such as stress management techniques, ensuring a holistic approach to patient care.
• Educate patients about the chronic nature of coronary artery disease and the need for long-term management, encouraging active patient involvement in care and decision-making
• Schedule regular follow-up appointments to monitor progress, adjust treatments, and use validated assessment tools to track changes and treatment responses.

Recommended reads

1. Virani SS, Newby LK, Arnold SV, et al. 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2023 Sep 26;148(13):e148.
2. Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes [published correction appears in Eur Heart J. 2024 Apr 1;45(13):1145.
3. Collet JP, Thiele H, Barbato E, Barthelemy O, Bauersachs J, Bhatt DL, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289-1367.
4. Ibanez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C, Bueno H, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119-177.
5. Bueno H, Pocock S, Danchin N, et al. International patterns of dual antiplatelet therapy duration after acute coronary syndromes. Heart. 2017;103(2):132-138.
6. Fitchett D, Eikelboom J, Fremes S, et al. Dual antiplatelet therapy in patients requiring urgent coronary artery bypass grafting surgery: a position statement of the Canadian Cardiovascular Society. Can J Cardiol. 2009;25(12):683-689.
7. Baumbach A, Bourantas CV, Serruys PW, Wijns W. The year in cardiology: coronary interventions. Eur Heart J. 2020;41(3):394-405.